{"id":589382,"date":"2026-08-19T10:42:10","date_gmt":"2026-08-19T10:42:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/589382\/"},"modified":"2026-08-19T10:42:10","modified_gmt":"2026-08-19T10:42:10","slug":"mutant-kras-vaccine-for-pancreatic-cancer-prevention","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/589382\/","title":{"rendered":"Mutant KRAS Vaccine for Pancreatic Cancer Prevention"},"content":{"rendered":"<p data-path-to-node=\"24\">TARGETING pancreatic precursor lesions through <a href=\"https:\/\/www.emjreviews.com\/en-us\/amj\/oncology\/news\/pancreatic-cancer-vaccine-linked-to-extended-survival\/\" rel=\"nofollow noopener\" target=\"_blank\">a mutant KRAS vaccine<\/a> generated durable immune responses for long-term cancer interception. Pancreatic ductal adenocarcinoma is typically diagnosed at advanced stages, resulting in an overall five-year survival rate of only thirteen percent. Because precursor lesions like pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms evolve over more than a decade, intercepting malignant transformation represents a vital therapeutic window. Unlike established tumors that exhibit immunosuppressive microenvironments, pancreatic precancers provide a receptive setting for <a href=\"https:\/\/www.emjreviews.com\/en-us\/amj\/oncology\/symposium\/immunize-to-optimize-enhancing-cancer-care-through-vaccines-j330125\/\" rel=\"nofollow noopener\" target=\"_blank\">immune intervention<\/a>. A phase 1 clinical trial evaluated an off-the-shelf mutant KRAS vaccine in twenty asymptomatic individuals with hereditary predisposition, including germline variants in ATM, BRCA1, BRCA2, CDKN2A, or APC, alongside baseline radiographic pancreatic abnormalities.<\/p>\n<p>Robust Immunogenicity of the Mutant KRAS Vaccine<\/p>\n<p data-path-to-node=\"26\">The synthetic peptide vaccine formulated with poly-ICLC adjuvant targeted six common driver mutations, specifically G12D, G12V, G12R, G12A, G12C, and G13D. Immune monitoring demonstrated that ninety percent of participants mounted a significant mutant KRAS-specific T-cell response, achieving a median 18.2-fold increase in interferon-gamma-secreting cells. Responses occurred across diverse HLA alleles, validating the feasibility of an HLA-agnostic intervention. Furthermore, fifty percent of participants mounted detectable T-cell activity against all six evaluated antigens. Functional profiling confirmed robust polyfunctional CD4+ and CD8+ memory T-cell responses with secretion of interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. Longitudinal T-cell receptor sequencing showed that vaccine-induced memory clonotypes persisted in the peripheral repertoire for up to two years following <a href=\"https:\/\/www.cancerresearch.org\/immunotherapy-by-treatment-types\/cancer-vaccines\" target=\"_blank\" rel=\"noopener nofollow\">vaccination<\/a>.<\/p>\n<p>Clinical Tolerability and Premalignant Interception<\/p>\n<p data-path-to-node=\"28\">At a median follow-up of 16.5 months, no participants developed pancreatic ductal adenocarcinoma or required surgical intervention. Post hoc radiographic evaluation demonstrated pancreatic cyst regression or complete resolution in 37.5% of vaccinated patients, compared with 6.8% in an unvaccinated surveillance cohort. The mutant KRAS vaccine exhibited an exceptional safety profile consisting exclusively of grade 1 and grade 2 adverse events, most commonly mild injection-site erythema, fatigue, chills, and self-limiting flu-like symptoms. These clinical findings establish proof-of-concept for targeted immunotherapy in oncology, demonstrating that interception vaccines can activate durable immune surveillance against high-risk premalignant lesions.<\/p>\n<p data-path-to-node=\"30\">Reference<\/p>\n<p data-path-to-node=\"31\">Haldar SD et al. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Cancer Discov. 2026.<\/p>\n<p data-path-to-node=\"32\">Featured Image: PhotoByTawat on Adobe Stock.<\/p>\n","protected":false},"excerpt":{"rendered":"TARGETING pancreatic precursor lesions through a mutant KRAS vaccine generated durable immune responses for long-term cancer interception. Pancreatic&hellip;\n","protected":false},"author":2,"featured_media":589383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-589382","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/589382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=589382"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/589382\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/589383"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=589382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=589382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=589382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}